Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023473 (chronic myeloid leukemia)
 18,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The object of this study was to determine the allergenicity of goat milk (GM) and cow milk (CM) and that of their respective lactosera (GML and CML), by in vivo and in vitro assays. Two systemic tests for anaphylaxis were carried out in guinea pigs, the animals being sensitized orally with the 2 types of milk and lactosera. Sera were taken from the orbital sinus of the experimental animals at 0 and 22 d of the experiment to perform the serological study and the passive cutaneous anaphylaxis test. For the latter, the guinea pigs were sensitized passively with antibodies against the 4 antigen solutions. Enzyme-linked immunosorbent assay and Western blot were used to determine the specific antibodies of the isotypes immunoglobulin G1 and immunoglobulin G(Fc) developed against the same 4 antigen solutions. From these anaphylaxis and antibody-production tests, it was concluded that GM is hypoallergenic when compared with CM. The lactosera produced more closely grouped results, with values always below those of the corresponding milk. None of the proteins in the 4 immunizing solutions were identified as being their main allergen. These results show the hypoallergenicity of GM versus CM, and also that both casein and lactoserum proteins may be responsible for allergy in each case. To analyze the possibility of producing an innocuous food for those allergic to milk proteins, it would be of interest to identify the epitope(s) responsible for such allergenicity.
 ...
PMID:Evaluation of the allergenicity of goat milk, cow milk, and their lactosera in a guinea pig model. 1923 76

Imatinib mesylate is a drug that has been approved for treatment of advanced gastrointestinal stromal tumors (GISTs) and patients with leukemia such as chronic myeloid or Philadelphia chromosome-positive acute lymphoblastic. Although it has been described only in one patient with testicular hydrocele and gynecomastia in the literature, several cases of male gynecomastia have been reported with the use of imatinib mesylate in chronic myeloid leukemia (GML). Generally, male mastoplasia resolves after discontinuation of imatinib treatment. We report a 73-year-old male with metastatic GISTs who developed gynecomastia and unilateral testicular hydrocele while receiving imatinib mesylate. Nine months after commencing imatinib treatment, gynecomastia and testicular hydrocele were determined. Hormone analyses requested showed serum testosterone levels below and serum estrogen levels above normal limits. During the first month after discontinuing imatinib mesylate treatment, serum testosterone level was normal and there was a partial regression in gynecomastia and testicular hydrocele. To our knowledge, this is the second report of male gynecomastia following imatinib mesylate treatment of a patient with GIST. In conclusion, male patients who are to receive treatment with imatinib mesylate may be monitored for serum testosterone levels and for other reproductive hormone profiles before initiation of the treatment and their breasts may be examined during follow-up visits.
 ...
PMID:Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: a literature review. 2200 1